FOLD
$8.13
Amicus Therapeutics
($.06)
(.73%)
FOLD
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($0.32)
Revenue:  $44.33 Mil
Monday
Nov 4
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when FOLD reports earnings?
Beat
Meet
Miss

Where is FOLD's stock price going from here?
Up
Flat
Down
Stock chart of FOLD
Analysts
Summary of analysts' recommendations for FOLD
Score
Grade
Pivots
Resistance
$8.60
$8.46
$8.29

$8.15

Support
$7.98
$7.84
$7.67
Tweet
Growth
Description
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Peers
Regeneron PharmaceuticalsCelgeneInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonMylanZoetisPerrigo